Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Castration-resistant prostate cancer (CRPC) is a lethal malignancy with limited treatment options.
• Current therapies primarily focus on the androgen receptor pathway, which CRPC often evades.
• Emerging research highlights the FABP5-PPARγ-VEGF signaling axis as a critical driver of CRPC progression.

Purpose of the Study:

• To investigate the therapeutic potential of targeting the FABP5-PPARγ-VEGF axis in CRPC.
• To evaluate the efficacy of a novel chemical inhibitor, SBFI26, against CRPC.
• To elucidate the mechanism of action of SBFI26 in suppressing CRPC progression.

Main Methods:

• Utilized in vitro cell culture models (PC3-M cells) and orthotopic mouse models of CRPC.
• Administered SBFI26, a chemical inhibitor of Fatty Acid Binding Protein 5 (FABP5).
• Assessed effects on cell proliferation, migration, invasiveness, colony formation, primary tumor growth, and metastasis.

Main Results:

• SBFI26 significantly inhibited proliferation, migration, invasiveness, and colony formation of CRPC cells in vitro.
• SBFI26 treatment resulted in significant suppression of primary tumor growth and metastasis in orthotopic mouse models.
• The inhibitor functions by competitively binding to FABP5, blocking fatty acid uptake and subsequent PPARγ activation.

Conclusions:

• Targeting the FABP5-PPARγ-VEGF signaling axis represents a promising and novel therapeutic strategy for CRPC.
• SBFI26 demonstrates significant preclinical efficacy in inhibiting CRPC progression and metastasis.
• This approach offers a potential alternative to androgen-deprivation therapy for advanced prostate cancer.